Obese mice treated with tirzepatide showed switched-on brown fat, the heat-producing tissue that burns energy instead of storing it, according to a research group at the University of Barcelona. The effect appeared even when the treated animals were compared against mice fed exactly the same amount of food, which points to something the drug does to fat tissue beyond making animals eat less.
Marion Peyrou, a Ramon y Cajal researcher at the university’s Faculty of Biology and Institute of Biomedicine, is the lead researcher on the work, which also involved the Sant Joan de Deu Research Institute and the CIBER network on obesity and nutrition. “This activation is associated with an increased capacity to burn metabolic energy and with the production of batokines by brown adipose tissue, molecules that are beneficial for metabolism,” Peyrou said in the university’s account of the findings.
Pair-fed controls in the mouse experiment
The design matters more than the main result. According to the paper’s abstract, the team put mice on a high-fat diet until they became obese, then injected tirzepatide at 10 nanomoles per kilogram for five days, followed by 20 nanomoles per kilogram for another seven. A second group received no drug but was pair-fed, meaning each animal got the same quantity of food its drugged counterpart ate. Because tirzepatide suppresses appetite, comparing against freely eating animals would have mixed two effects together. Pair-feeding strips the appetite effect out and leaves whatever the drug does on its own.
Brown fat, UCP1 and the batokines
Brown adipose tissue is built to turn fuel into heat, and the mechanism runs through a mitochondrial protein called UCP1, a process described in a review of brown fat as an obesity target. In the Barcelona data, tirzepatide raised UCP1 in brown fat along with respiratory-chain proteins SDHB and COXI and the mitochondrial marker TOM20, and the tissue’s temperature and oxidative capacity increased. That combination is what the researchers describe as a higher capacity to burn energy.
The same tissue also released more batokines, signalling molecules that brown fat sends into the bloodstream. The paper names two that rose, Bmp8b and Cxcl14. Batokines are the reason brown fat is studied for effects on blood sugar and lipids that go beyond the calories it burns directly, and the university release on EurekAlert frames this as a possible route to metabolic benefits independent of weight loss.
The group around Peyrou, listed in the ScienceDaily write-up of the release, includes Alberto Mestres-Arenas, Tania Quesada-Lopez, Albert Blasco-Roset, Marta Giralt, Francesc Villarroya and Anna Planavila. The paper reads as a targeted test of one tissue rather than a broad survey of the drug’s effects, and its framing question is narrow: when appetite is held equal, does tirzepatide still change how fat tissue spends energy?
White fat behaved differently. Both visceral and subcutaneous white depots changed their lipid metabolism, but the abstract reports no signs of the “browning” that white fat can sometimes undergo. The paper’s title, which calls brown fat “a key target,” reflects that split: the drug appeared to act on one fat type far more than the other.
Limits of a result in mice
Peyrou and colleagues were direct about the boundary. The findings come from mice and cannot yet be assumed to apply in the same way to people, the team said, noting that species differ in how metabolism is regulated and how drugs are handled. How much brown fat tirzepatide would switch on in a person was not tested here.
Tirzepatide is an approved human drug, sold as Mounjaro for type 2 diabetes and as Zepbound for weight management, so any brown-fat effect in people would be layered onto treatments patients already use. The FDA approved it as Zepbound in November 2023 for chronic weight management, describing it as acting on the gut-hormone receptors GLP-1 and GIP to suppress appetite and reduce food intake. In two trials of 2,519 patients on Zepbound and 958 on placebo, the 15 mg dose produced roughly 18 percent weight loss in people without diabetes. The Barcelona work does not revise any of those trial figures, which came from people rather than rodents. It proposes an additional, tissue-level mechanism that would have to be confirmed in clinical studies.
The published figures also come from short exposures: twelve days of dosing in a high-fat-diet model. Whether brown fat stays activated over months of treatment, and whether the batokine signal translates into measurable changes in glucose or lipids in people, are questions the study leaves for later work.
The research appears in the journal Biomedicine and Pharmacotherapy, volume 195, article 119057, with Peyrou, Marta Giralt and Francesc Villarroya named as directing the investigation on the ScienceDirect record. Its narrow claim is a mouse-level explanation of why a GIP and GLP-1 drug may change energy use in a way that pair-fed controls did not.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
- Supplements now rank as the fifth-leading cause of death from liver disease.
- Herbal supplements are landing Americans in the hospital with liver damage, doctors warn
- General Motors is switching on cameras that record inside your vehicle by update
- A geomagnetic storm is forecast to hit Earth today, pushing the northern lights unusually far south
